Your Followed Topics

25.00%
health11h ago

Patients, doctors hail ‘revolutionary’ new drug for pancreatic cancer

https://www.wbez.org/health-medicine/2026/05/31/pancreatic-cancer-daraxonrasib-early-access-treatmenthttps://www.sciencenews.org/article/pancreatic-cancer-pill-daraxonrasibhttps://www.npr.org/2026/05/31/nx-s1-5841859/experimental-pill-new-hope-pancreatic-cancer
Wbez.org and 5 more
Patients, doctors hail ‘revolutionary’ new drug for pancreatic cancer Open in Wbez.org
Highlights
  • In previously treated metastatic pancreatic cancer, daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy.
  • The daily pills nearly doubled survival time, with fewer severe side effects, in a study that randomly assigned the experimental drug or more chemotherapy to 500 patients whose metastatic, or spreading, cancer had quit responding to prior treatment.
  • Revolution Medicines' drug uses what's essentially a molecular glue to bind with multiple KRAS subtypes.

Virality Score Timeline

Vote 15
0

References

A new pancreatic cancer pill may be a game changer for patients

A new pancreatic cancer pill may be a game changer for patients

Experimental pill promises new hope for deadly pancreatic cancer

Experimental pill promises new hope for deadly pancreatic cancer

Experimental drug shows promise against deadly pancreatic cancer

Experimental drug shows promise against deadly pancreatic cancer

Experimental pill promises new hope for deadly pancreatic cancer | CNN

Experimental pill promises new hope for deadly pancreatic cancer | CNN

Experimental pill promises new hope for deadly pancreatic cancer

Experimental pill promises new hope for deadly pancreatic cancer

Related Topics

0 Comments

Be the first to comment

Add your thoughts and get the conversation going.

Top 344 Internet News Today

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement